INTRODUCTION
The endoplasmic reticulum (ER) functions primarily to process newly synthesized secretory and transmembrane proteins. Abnormal accumulation of unfolded proteins in this compartment causes a state of ''ER stress,'' which is a hallmark feature of secretory cells and many diseases, including diabetes, neurodegeneration, and cancer (Hetz et al., 2013) . Adaptation to protein-folding stress is mediated by activation of an integrated signal transduction pathway dubbed the ER stress or unfolded protein response (UPR) that signals through three distinct stress sensors located at the ER membrane: IRE1a, ATF6, and PERK (Hetz et al., 2013) . The most conserved UPR arm is IRE1a. During ER stress, this kinase oligomerizes, autophosphorylates, and uses its endoribonuclease activity to excise a 26-nucleotide fragment from the unspliced Xbp1 mRNA (Yoshida et al., 2001 ) that gives rise to functional XBP1, a potent multitasking transcription factor that promotes ER chaperone expression and regulates distinct sets of target genes in a cell type-specific manner (Lee et al., 2003b; Yoshida et al., 2001) .
Aggressive tumors evolve strategies to thrive in adverse conditions that induce ER stress such as hypoxia, nutrient starvation, and oxidative stress by adjusting ER protein folding capacity (Hetz et al., 2013) . In cancer cells, XBP1 confers drug resistance by preventing drug-induced cell-cycle arrest, mitochondrial permeability, and apoptosis (Gomez et al., 2007) . XBP1 drives multiple myeloma (Lee et al., 2003a) and chronic lymphocytic leukemia . We recently demonstrated that XBP1 facilitates triple-negative breast cancer progression by promoting tumor cell survival and metastatic capacity under hypoxic conditions (Chen et al., 2014) . XBP1 expression in cancer cells directly supports tumorigenesis, but whether it also creates a tumor-permissive immune milieu is unknown.
In most solid cancers, nonmalignant cells such as leukocytes, vascular cells, and fibroblasts are exposed to similarly harsh microenvironmental conditions while stimulating tumor development and progression (Whiteside, 2008) . Leukocyte recruitment to established cancers has pro-tumoral effects, including secretion of growth factors that enhance tumor cell proliferation and metastasis (Coussens and Werb, 2002) , the induction of tumor vascularization via paracrine mechanisms (De Palma et al., 2007) , and the orchestration of immunosuppressive networks (Zou, 2005) that restrain the protective role of the scarce leukocytes with inherent anti-tumor capacity. Ovarian tumors subvert the normal activity of infiltrating dendritic cells (DCs) to inhibit the function of otherwise protective anti-tumor T cells (Curiel et al., 2003; Scarlett et al., 2012) . Eliminating or ''re-programming'' tumor-associated DCs (tDCs) in vivo can abrogate ovarian cancer (OvCa) progression Huarte et al., 2008; Scarlett et al., 2012) , but the precise molecular pathways that tumors exploit in DCs to co-opt their activity remain poorly understood. Here, we uncover an unexpected role for the ER stress response factor XBP1 as a crucial driver of DC dysfunction in OvCa-bearing hosts.
RESULTS

Robust XBP1 Activation in OvCa-Associated DCs
Myeloid cells with phenotypic features of regulatory DCs commonly infiltrate ovarian tumors and promote malignant progression by preventing activation and expansion of tumor-reactive T cells . We sought to determine whether XBP1 might drive tumor growth by inhibiting DC-dependent anti-cancer immunity. Splenic and draining lymph node DCs from mice bearing aggressive primary and metastatic OvCa (Conejo-Garcia et al., 2004; Scarlett et al., 2012) showed increased splicing of Xbp1 mRNA compared with DCs from naive hosts ( Figures 1A, S1A , and S1B). However, this process was markedly enhanced in tDCs (Figures 1A and S1C-S1F). Quantitative analyses confirmed robust expression of total and spliced Xbp1 mRNA in tDCs, compared with closely related CD11c + MHC-II + CD11b + splenic DCs (sDCs; Figure S1G ) from naive or OvCa-bearing mice ( Figure 1B ). Consistently, tDCs had increased nuclear XBP1 protein compared with control DCs from non-tumor sites ( Figure 1C ). Further, marked upregulation of canonical XBP1 target genes ERdj4 and Sec61a1 (Acosta-Alvear et al., 2007; Lee et al., 2003b ) ( Figure 1D ) and general ER stress response markers Hspa5 (BiP) and Ddit3 + CD8a low tDCs were isolated from advanced p53/K-ras-driven ovarian tumors or from malignant ascites of mice bearing aggressive ID8-Defb29/Vegf-A ovarian carcinoma for 4-5 weeks, and their identity as bona fide classical DCs was confirmed by quantifying Clec9A/DNGR-1 and Zbtb46 expression (see also Figure S1 (CHOP) occurred only in tDCs ( Figure 1E ). Constitutive Xbp1 splicing was also observed in tDCs isolated from multiple human OvCa specimens ( Figures 1F, S1H , and S1I), and expression levels of ER stress markers BiP and CHOP positively correlated in these human samples ( Figure 1G ). Interestingly, increased CHOP expression in tDCs was associated with reduced T cell infiltration in human OvCa specimens ( Figure 1H ), suggesting that ER-stressed DCs may regulate T cell anti-tumor responses. Hence, DCs in the OvCa microenvironment exhibit marked upregulation of ER stress response markers and robust XBP1 activation.
DC-Intrinsic XBP1 Is Required for Optimal OvCa Progression
We next developed aggressive orthotopic ovarian tumors in conditional knockout female mice lacking functional XBP1 in DCs. Genetically modified mice harboring exon 2 of Xbp1 flanked by two loxP sites (Lee et al., 2008) were crossed with mice expressing Cre recombinase under control of the integrin alpha X (Itgax) promoter (termed CD11c-Cre) (Figures S2A-S2C) that deletes selectively in conventional DCs (Caton et al., 2007) . Consistent with recent reports (Osorio et al., 2014) , conditional XBP1 deletion through CD11c-controlled Cre solely affected the proportion and number of splenic CD8a + DCs (Figures S2D-S2L ). The frequency of tDCs, which are mainly CD8a-low ( Figure S1E ), was not altered in mice bearing orthotopic OvCa ( Figures S2G-S2J ), indicating that XBP1 is dispensable for DC survival in the OvCa microenvironment. However, the development of p53/K-ras-driven primary OvCa was significantly compromised in irradiated hosts reconstituted with XBP1 f/f CD11c-Cre donor bone marrow (BM) compared with control hosts transplanted with XBP1-sufficient (XBP1 f/f ) littermate BM (Figures 2A and 2B ). Tumor growth was also inhibited in mice bearing primordial p53/K-ras-driven OvCa upon intraperitoneal (i.p.) injection of XBP1-deficient, but not WT, BM-derived DCs (BMDCs) (Figures 2C and 2D) . XBP1 in the tumor microenvironment show enhanced capacity to restrain tumor growth. Since the vast majority of OvCas are diagnosed at advanced stages, with disease spread throughout the peritoneal cavity, we examined how DC-localized XBP1 impacts progression of orthotopic tumors that closely recapitulate human metastatic OvCa (Conejo-Garcia et al., 2004) . Notably, OvCa-bearing female mice lacking functional XBP1 in DCs demonstrated reduced peritoneal tumor burden ( Figures 2E and 2F) , impaired ascites accumulation ( Figure 2G ), and diminished tumorinduced splenomegaly ( Figure 2H ) compared with control (XBP1 f/f ) littermates. Consequently, these hosts displayed an $30% increase in median survival compared with control littermates ( Figure 2I ). Similar survival results were observed in XBP1 f/f CD11c-Cre mice developing parental orthotopic ovarian tumors (Roby et al., 2000) that do not ectopically express Defb29 and Vegf-A ( Figure 2J ). Further confirming the detrimental role of DC-intrinsic XBP1 in OvCa, implantation of malignant cells admixed with WT BMDCs markedly promoted the growth of solid ID8-based ovarian tumors, whereas XBP1-deficient BMDCs significantly impaired this process ( Figures 2K and 2L ).
Together, these results demonstrate that XBP1 expression in DCs is necessary for the accelerated and aggressive progression of primary and metastatic OvCas in three preclinical models of disease.
Byproducts of Lipid Peroxidation Trigger ER Stress in DCs
Constitutive XBP1 activation in tDCs suggested that cancerderived factors in the tumor microenvironment might trigger ER stress in innate immune cells to blunt anti-tumor immunity. Interestingly, neither tumorigenic/immunosuppressive cytokines commonly enriched at tumor sites nor hypoxia-mimicking conditions caused robust XBP1 activation in naive DCs . Abnormal intracellular accumulation of peroxidized lipids is a common feature of dysfunctional DCs infiltrating several human and murine cancers (Herber et al., 2010; Ramakrishnan et al., 2014) . Intracellular lipid oxidation by reactive oxygen species (ROS) generates multiple reactive byproducts such as the unsaturated aldehyde 4-hydroxy-trans-2-nonenal (4-HNE), shown to induce protein-folding stress by forming stable adducts with ER-resident chaperones (Vladykovskaya et al., 2012) . Hence, we hypothesized that this diffusible and highly reactive aldehyde (Uchida et al., 1999 ) might trigger ER stress in tDCs. OvCa-associated DCs demonstrated significantly higher amounts of intracellular lipids and augmented ROS levels in comparison with control sDCs isolated from the same host or from naive mice (Figures 3A and 3B) . Consistent with active lipid peroxidation, we found intracellular 4-HNE-protein adducts in tDCs isolated from human and mouse tumors ( Figure 3C ), and increased levels of this aldehyde were present in tDCs compared with sDC of OvCa-bearing mice ( Figure 3D ). Extracellular 4-HNE was not enriched in cell-free ascites or serum from OvCabearing hosts (Figures S3D and S3E) , suggesting that this reactive aldehyde is mostly generated intracellularly due to the high lipid and ROS content in tDCs (Figures 3A and 3B) . Indeed, naive sDCs exposed to cell-free OvCa ascites rapidly generated intracellular 4-HNE-protein adducts in a dose-dependent manner ( Figure 3E ). Proteomic analyses confirmed the presence of several intracellular proteins modified by the endogenous 4-HNE generated in naive DCs exposed to OvCa ascites supernatants, but not in control untreated DCs (Table S1 ). Of note, ascites-induced 4-HNE modified key ER-resident chaperones such as Grp78/BiP and ERdj3/Dnajb11 ( Figures 3F and 3G ). Induction of 4-HNE-protein adducts by ascites was inhibited when DCs were treated with the ROS-scavenging agent vitamin E or with hydralazine ( Figure 3H ), a hydrazine derivative (Figure S3F) previously shown to sequester reactive lipid peroxidation byproducts (Galvani et al., 2008) . Treatment of freshly isolated tDCs with either vitamin E or hydralazine inhibited Xbp1 splicing and prevented induction of general ER stress response markers triggered by ascites exposure (Figures 3I and 3J) . Further, induction of Xbp1 splicing and upregulation of ER stress response markers was observed in naive sDC exposed to 4-HNE concentrations generating intracellular adduct levels similar to those generated upon incubation with cell-free ascites ( Figures S3G-S3I ). Together, these data indicate that lipid peroxidation byproducts, abundant in OvCa tDCs, promote ER stress and constitutive XBP1 activation.
Constitutive XBP1 Activation Disrupts DC Homeostasis
Transcriptional profiling of WT versus XBP1-deficient DCs in OvCa ascites identified 416 significantly downregulated and 237 significantly upregulated genes (Table S2 ). These altered gene subsets were analyzed to identify transcriptional regulators that may explain the observed mRNA changes. Several predicted regulators were identified ( Figure S4A ), and XBP1, as expected, was a key node in the most highly represented gene network emerging from this analysis ( Figure S4B ). Interestingly, gene networks regulated by the immunosuppressive transforming growth factor-b (TGF-b), but not TGF-b itself, were suppressed in XBP1-deficient tDCs ( Figure S4A ). Multiple known XBP1 and UPR target genes (Acosta-Alvear et al., 2007; Lee et al., 2003b) were markedly repressed in XBP1-deficient tDCs ( Figure 4A ), confirming sustained ER stress in DCs infiltrating OvCa. Expression of known regulated IRE1a-dependent decay (RIDD) target mRNAs (Hetz et al., 2013; Hollien et al., 2009; Osorio et al., 2014) was unchanged between WT and XBP1-deficient tDCs ( Figure S4C ), ruling out IRE1a artificial overactivation due to absence of functional XBP1. We found four significantly enriched functional categories, including carbohydrate and lipid metabolic processes, protein localization and transport, and regulation of cell communication ( Figure S4D ). Of particular interest, tDCs devoid of XBP1 displayed marked downregulation of multiple genes involved in lipid metabolic pathways and especially, in triglyceride biosynthesis ( Figure 4B ). Given the strong association between excessive lipid accumulation and DC dysfunction in cancer (Herber et al., 2010; Ramakrishnan et al., 2014) , we investigated XBP1 as a potential mediator of this process. Consistent with sustained ER stress at tumor locations, OvCa-associated DCs exhibited marked upregulation of multiple XBP1-controlled triglyceride biosynthetic genes ( Figure 4B ), including Agpat6, Fasn, Scd2, and Lpar1 ( Figure S5A ), and these genes were rapidly induced in naive sDCs exposed to 4-HNE ( Figure S5B ). OvCa-infiltrating DCs lacking XBP1 showed reduced intracellular lipid content compared with WT tDCs ( Figure 4C ) and displayed a marked decrease in the number of cytosolic lipid droplets ( Figures 4D and 4E ), as well as reduced intracellular levels of total triglycerides ( Figure 4F ). Other lipid classes were unaffected ( Figure S5C ), and these observations were confirmed by analyzing cell-free ascites supernatants (Figure S5D ). Decreased intracellular lipid content in XBP1-deficient tDCs was not due to defective expression of genes encoding scavenger receptors (Cd36, Cd68, Msr1) implicated in extracellular lipid uptake ( Figure S5E ). Notably, exposure to cell-free OvCa ascites augmented the intracellular lipid content of mouse (E) Dose-dependent increase in intracellular 4-HNE-protein adducts in sDCs exposed to ascites supernatants. (F) MS/MS spectrum on the doubly charged precursor at m/z 909.00, identifying a tryptic peptide with 4-HNE forming a Michael adduct on the Lys214 residue of the peptide from the 78 kDa glucose-regulated protein precursor (GRP78/BiP). (G) MS/MS spectrum on the triply charged precursor at m/z 643.32, identifying a tryptic peptide with 4-HNE forming a Michael adduct on the Lys82 residue of the peptide from the dnaJ homolog subfamily B member 11 precursor (ERdj3/Dnajb11).
(H) Intracellular levels of 4-HNE protein adducts in sDCs exposed to cell-free ascites in the presence or absence of VitE or Hydralazine (Hlz) for 18 hr.
(I and J) tDC were pretreated with VitE or Hlz and then incubated in normal media (gray bars) or in media supplemented with 25% cell-free ascites (green bars) for 18 hr. Expression of the indicated transcripts was assessed via RT-qPCR. Data are normalized to Actb expression in each sample. # p < 0.05 compared with tDC in ascites-free media. *p < 0.05 compared with ascites-exposed untreated tDC. Error bars represent SEM.
tDCs and was prevented by concurrent treatment with TOFA, an inhibitor of fatty acid synthesis ( Figures 4G and S5F ). Pharmacological inhibition of IRE1a/XBP1 activation using the IRE1a inhibitor 4m8c also reduced ascites-driven lipid biogenesis in tDCs ( Figures 4G and S5F ). Consistent with ROS as key generators of XBP1-activating 4-HNE (Figure 3) , treatment of tDCs with the global ROS scavenger vitamin E, but not with the superoxide-specific scavenger Tiron reduced intracellular lipid content ( Figures 4G and S5F ). Further, sequestering intracellular 4-HNE using hydralazine also prevented ascites-induced lipid biogenesis in tDCs ( Figure S5G ). Taken together, the transcriptomic and functional data indicate that sustained activation of XBP1 disrupts intracellular lipid homeostasis in OvCa-associated DCs.
XBP1-Deficient tDCs Support T Cell Activation
Aberrant lipid accumulation by tDCs obstructs their normal antigen-presenting capacity, ultimately blunting anti-tumor immune responses (Herber et al., 2010; Ramakrishnan et al., 2014) . T cells are the sole immune population that exerts significant pressure against OvCa, and the magnitude of intra-tumoral T cell infiltration strongly correlates with better outcome in OvCa patients (Curiel et al., 2003; Zhang et al., 2003) . Hence, XBP1-deficient tDCs with reduced intracellular lipids might support rather than repress T cell activation and function at tumor sites. Incubation of BMDCs in tumorconditioned media (TCM) induced Xbp1 splicing ( Figure S6A ) and subsequent triglyceride accumulation ( Figure S6B ), leading to decreased surface expression of MHC-I complexes loaded with intracellularly processed peptide (ovalbumin [OVA]-derived SIINFEKL) ( Figure S6C ). Accordingly, BMDCs pulsed with fulllength OVA protein in the presence of TCM, compared with normal culture media, had reduced capacity to induce OT-1 T cell proliferation ( Figure 5A ). This impairment was also observed upon incubation with the ER stressor tunicamycin or by enforcing lipid accumulation using oleate during antigen loading ( Figure 5A ). In contrast, XBP1-deficient BMDCs unable to accumulate triglycerides upon TCM exposure ( Figure S6B ) did not show significant reduction in surface levels of peptide-loaded MHC-I complexes when pulsed under this condition ( Figure S6C ). This effect was not due to enhanced OVA cleavage ( Figure S6D ) or increased expression of MHC-I by XBP1-deficient BMDCs ( Figure S6E ). Consequently, BMDCs lacking XBP1 demonstrated enhanced capacity to induce the proliferation of OT-1 T cells when pulsed with OVA under TCM, compared with their WT counterparts pulsed likewise ( Figure 5B ). XBP1-deficient tDCs pulsed with full-length OVA or apoptotic OVA-expressing tumor cells in the presence of ascites also had enhanced capacity to induce OT-1 T cell expansion, compared with WT tDCs (Figures 5C and S6F-S6H), and these differences were not due to reduced PD-L1 expression by XBP1-deficient tDC ( Figure S6I ). Consistent with impaired lipid accumulation upon global ROS scavenging and IRE1a/1 inhibition ( Figure 4G ), pre-treatment of WT tDC with vitamin E phenocopied the improved antigen-presenting capacity of XBP1-deficient tDCs ( Figure 5C ). Further supporting the enhanced function of XBP1-deficient DCs at tumor locations, p53/K-ras ovarian tumors developed in irradiated hosts reconstituted with XBP1 f/f CD11c-Cre BM (Figure 2A ) demonstrated an $7-fold increase in the levels of intratumoral T cell infiltration compared with tumors developed in mice reconstituted with WT BM ( Figure S6J ). Most of these CD4 + T cells were antigen experienced (CD44 + ), and a significant proportion expressed the Th1-polarizing transcription factor T-bet ( Figure S6K ). The majority of CD8 + T cells present in p53/K-ras tumors generated in XBP1-deficient hosts also expressed CD44 and a proportion of those produced Granzyme B in situ ( Figure S6L ). Reduced PD-1 levels were observed on these cells compared with the few CD8 + T cells poorly infiltrating p53/K-ras tumors developed in mice reconstituted with WT BM ( Figure S6M ). While PD-1 levels remained unaltered on peritoneal T cells in XBP1 f/f or XBP1 f/f CD11c-Cre mice harboring metastatic ID8-based OvCa (Figure S6N ), the latter demonstrated a marked increase in the proportion of infiltrating CD44 + IFNg-secreting CD8 + and CD4 + T cells at tumor sites ( Figures 5D and 5E ). In addition, the proportion of Foxp3 + T regulatory cells infiltrating tumor locations was significantly lower in XBP1-deficient hosts ( Figure 5F ). To functionally demonstrate that the enhanced activity of XBP1-deficient DCs in OvCa results in improved T cell-mediated anti-tumor responses, orthotopic ovarian tumors were developed in WT or XBP1-deficient hosts, and T cells were obtained from spleens and draining lymph nodes 30 days after tumor implantation. Isolated T cells were independently transferred into naive mice, and hosts were then challenged with ovarian tumors in the flank. Notably, T cells obtained from tumor-bearing mice lacking XBP1 in DCs demonstrated improved capacity to restrain tumor growth in adoptively transferred hosts, compared with untreated mice or control mice receiving T cells isolated from WT OvCa-bearing mice (Figures 5G and 5H) . Together, these data indicate that constitutive XBP1 activation promotes anti-tumor immune tolerance by OvCa-associated DCs.
Therapeutic XBP1 Silencing in tDCs Extends Host
Survival by Inducing Anti-tumor Immunity Silencing XBP1 expression in OvCa-associated DCs could potentially restore their immunogenic attributes in situ to promote the function of infiltrating anti-tumor T cells. To selectively target XBP1 in tDCs, we utilized our previously optimized system of polyethylenimine (PEI)-based nanoparticles encapsulating siRNA (Cubillos-Ruiz et al., 2009 . These nanocomplexes are preferentially and avidly engulfed by abundant phagocytic tDCs upon i.p. injection, enabling selective in vivo gene silencing. Also, PEI-based nanoparticles inherently activate OvCa-associated DCs by triggering TLR signaling that induces potent immunoadjuvant activity against tumors (Cubillos-Ruiz et al., 2009) . Confirming previous findings, nanoparticles were selectively taken up by tDCs present in malignant ascites of mice bearing metastatic OvCa ( Figure S7A ). PEI-based nanocomplexes delivering Xbp1-specific siRNA induced $65% gene silencing in target tDC compared with control luciferase-targeting siRNA nanoparticles ( Figure S7B ). The functional effects of gene silencing were confirmed by the decreased expression of the canonical XBP1 targets EDEM and Sec61a1, as well as lipid biosynthesis-related Agpat6 and Scd2 in tDCs ( Figure S6C ). Further, tDCs isolated from mice treated with either XBP1-or IRE1a-targeting nanoparticles demonstrated reduced triglyceride levels compared with control tDCs (Figure S7D ), and the in vivo proliferation of adoptively transferred CFSE-labeled OT-1 T cells in the OvCa microenvironment was significantly enhanced in mice pulsed i.p. with full-length OVA protein when XBP1 expression was specifically silenced in tDCs ( Figures  6A-6C ). Therapeutic administration of Xbp1-silencing nanocomplexes reduced the number of metastatic cancer cells in the peritoneal cavity ( Figure 6D ) and diminished malignant ascites accumulation ( Figure 6E ). These effects occurred concomitantly with enhanced infiltration of endogenous antigen-experienced/ activated T cells at tumor locations compared with control nanoparticles ( Figure 6F ). Indeed, silencing XBP1 expression in tDCs markedly enhanced the capacity of infiltrating T cells to respond to tumor antigens, as evidenced by ex vivo interferon-g (IFN-g) and Granzyme B secretion using BMDCs pulsed with tumor antigens ( Figure 6G ). Splenic T cells isolated from mice treated with XBP1-silencing nanocomplexes also demonstrated improved responses upon exposure to tumor antigens in similar re-call assays ( Figure 6H ), indicating development of enhanced anti-tumor memory responses. These data reinforce the concept that abrogating XBP1 function in tDCs enables the activation and expansion of endogenous anti-tumor T cells in vivo.
To determine whether abrogation of the IRE1a/XBP1 pathway selectively in tDCs had significant therapeutic effects, mice bearing aggressive orthotopic ovarian tumors were i.p. treated with saline, non-targeting or gene-specific siRNA-PEI nanocomplexes. Treatments started 12 days after tumor implantation, and injections were administered every 4 days for a period of 3 weeks. Interestingly, WT mice treated with either XBP1-or IRE1a-silencing nanoparticles demonstrated a marked increase in survival compared with control groups, reinforcing dependence of this phenotype on spliced Xbp1 rather than RIDD (Figure 7A) . However, Rag2-deficient hosts bearing ovarian tumors were unable to respond to this treatment, demonstrating that an intact adaptive immune system is necessary for the observed therapeutic benefit ( Figure 7B ). Together, these data indicate that targeting the IRE1a/XBP1 branch of the ER stress response in tDCs induces protective immune responses against OvCa.
DISCUSSION
Here we uncover an unexpected role for the ER stress response factor XBP1 as a central driver of DC malfunction in the tumor microenvironment. Our findings suggest a strategy whereby a lethal cancer exploits the most conserved arm of the ER stress response in tumor-resident DCs to disrupt their homeostasis, alter their local antigen-presenting capacity, and ultimately evade T cell-mediated immune control. While the ER stress response, and especially XBP1 activation, was previously shown to promote tumorigenesis, we now propose that this integrated cellular pathway further supports malignant progression by inhibiting the development of protective anti-tumor immunity via manipulation of normal DC function.
Gabrilovich and colleagues have elegantly demonstrated that cancer-associated DCs accumulate substantial amounts of oxidized lipids that diminish their antigen-presenting ability (Herber et al., 2010; Ramakrishnan et al., 2014) . Our transcriptional and functional analyses suggest that XBP1 plays a crucial role in promoting aberrant lipid accumulation by dysfunctional tDCs and that lipid peroxidation byproducts, like 4-HNE, sustain ER stress and fuel constitutive XBP1 activation in tDCs. Interestingly, 4-HNE was shown to induce the UPR in endothelial cells by forming covalent adducts with ER resident chaperones, thereby promoting vascular inflammation and atherosclerosis (Vladykovskaya et al., 2012) . Consistent with previous reports linking XBP1 and lipid biosynthesis (Lee et al., 2008; Sriburi et al., 2004) , we found that enhanced intracellular lipid accumulation by tDCs required ROS generation and IRE1a/XBP1 activation. Interestingly, exposure to 4-HNE is sufficient for promoting fat accumulation in worms and mice (Singh et al., 2008 (Singh et al., , 2009 ). Other lipid peroxidation byproducts like acrolein, malondialdehyde, and 4-hydroxyhexenal form stable adducts with cellular proteins (Negre-Salvayre et al., 2008) , suggesting that they might also induce immunosuppression in the tumor microenvironment by triggering ER stress in infiltrating innate immune cells. Further, chemotherapeutic agents are known to induce oxidative stress and subsequent 4-HNE generation (Velez et al., 2011) , suggesting that chemotherapy might promote ''tumorigenic ER stress'' in cells of the tumor microenvironment. This is particularly relevant to OvCa, as patients diagnosed with this disease show persistent, refractory, or recurrent cancer following treatment with surgery and first-line chemotherapy. Notably, the status of lipid peroxidation at the time of tumor removal has been suggested as a putative marker of disease recurrence in breast cancer patients (Herrera et al., 2014) .
Our findings suggest a model in which reactive metabolic byproducts induced by the tumor microenvironment, like 4-HNE, can initiate and sustain pro-tumorigenic ER stress in infiltrating tDCs. Constitutive activation of the IRE1a/XBP1 arm through this process disrupts global tDC homeostasis and consequently inhibits tDC capacity to locally support T cell-mediated antitumor responses. Since splenic and draining lymph node DCs of OvCa mice also showed increased levels of Xbp1s compared with naive hosts, it is reasonable to consider that XBP1 might also regulate anti-tumor immunity by operating in DCs residing in lymphoid organs that may have migrated from the primary tumor site.
Activating T cell immunity to eliminate tumor cells is the most promising anti-cancer strategy since the development of chemotherapy, as demonstrated by the shrinkage of melanoma in response to checkpoint blockers. Further, adoptively transferred anti-tumor T cells (expanded from tumor specimens or genetically manipulated) can elicit robust and long-lasting antitumor responses (Bollard et al., 2007; Morgan et al., 2006) . However, in most cases, the optimal cytotoxic activity of such tumor-reactive T cells is drastically reduced precisely because cancer-associated DCs are unable to support T cell function (Curiel et al., 2003; Scarlett et al., 2012) . Our results reveal that DC-specific deletion of XBP1 can extend host survival by converting immunosuppressive tDCs into activators of type 1 immunity in OvCa-infiltrating T cells. Indeed, therapeutic silencing of XBP1 in tDCs using siRNA-encapsulating nanocarriers reversed their immunosuppressive phenotype and prolonged host survival by inducing protective anti-tumor immune responses. Novel and more effective therapeutic strategies are urgently needed to improve the dismal prognosis of patients with metastatic OvCa and other lethal cancers. Our study demonstrates the feasibility and immunotherapeutic potential of targeting ER stress-driven XBP1 selectively in tDCs using a nanotechnology-based system that may slow or prevent the usually inevitable recurrence observed in OvCa patients who have been ''optimally'' debulked. Targeting IRE1a/XBP1 signaling in cancer-bearing hosts with small molecule IRE1a inhibitors could induce two parallel, mutually reinforcing anti-tumor mechanisms: the direct inhibition of cancer cell survival and the simultaneous induction of protective anti-tumor immunity.
EXPERIMENTAL PROCEDURES
Tissues, Mice, and Cell Lines Stages III-IV human OvCa specimens and malignant ascites samples were procured through Surgical Pathology at Weill Cornell under an approved protocol where research samples remained unidentified. Tumor single-cell suspensions were generated as described (Conejo-Garcia et al., 2004) . Malignant peritoneal ascites samples from patients with metastatic OvCa were centrifuged for 10 min at 1,300 rpm, and red blood cells were lysed prior to fluorescence-activated cell sorting (FACS) analysis. Mice were housed at the animal facilities of Harvard School of Public Health, Weill Cornell, or The Wistar Institute. Our Institutional Animal Care and Use Committees approved all animal experiments described in this study. Transgenic mouse strains and tumor models used are described in the Supplemental Experimental Procedures.
Isolation of Human and Mouse DCs
Human patient OvCa-associated DCs (CD45 + CD3
were sorted from tumor single-cell suspensions or malignant ascites using flow cytometry, following the gating strategy in Figure S1 . f/f CD11c-Cre (XBP1 deficient) BM via incubation in media supplemented with 20 ng/ml recombinant granulocyte macrophage colony-stimulating factor (GMCSF) (Gemini) . Cells were harvested at day 7 of expansion and used directly for subsequent in vitro or in vivo functional assays.
Reagents and In Vitro Cellular Treatments
Murine recombinant cytokines were purchased from Peprotech. Cobalt chloride (10-100 mM), tunicamycin (1 mg/ml), Tiron (100-500 mM), vitamin E (a-tocopherol, 50-100 mM) and hydralazine (100 mg/ml) were from Sigma. 2 0 ,7 0 -dichlorofluorescin diacetate (DCFDA) staining was utilized for intracellular ROS detection (Abcam). Purified 4-HNE (Cayman Chemical) and 4-HNE-protein adducts in ascites samples and DCs were detected and quantified through competitive ELISA (Cell Biolabs). 5-tetradecyl-oxy-2-furoic acid (TOFA) (Cayman Chemical) was used at a final concentration of 5 mg/ml to inhibit fatty acid synthesis in DCs. The IRE1a-specific inhibitor 4m8c (Millipore) was used at 10 mM and DQ-OVA (Invitrogen) at 50 mg/ml. Cell-free (0.22 mmfiltered) TCM was harvested from ID8-Defb29/Vegf-A OvCa cells grown to confluency in complete Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
RNA-seq and DC Transcriptional Profile tDCs were sorted from peritoneal wash samples of XBP1 f/f or XBP1 f/f CD11c-Cre female mice (n = 3 per group) bearing aggressive ID8-Defb29/Vegf-A ovarian tumors for 3 weeks. Total RNA was isolated using the miRVANA miRNA isolation Kit (Life Technologies), further concentrated via RNeasy MinElute columns (QIAGEN) and RNA quality and integrity confirmed in an Agilent Bioanalyzer 2100. In all cases, RINs were 9.50 or higher. mRNA libraries were generated and sequenced at the Weill Cornell Epigenomics Facility. All primers used in this study are described in Table S3 ; Supplemental Information for details.
Flow Cytometry and Lipid Staining
Intracellular lipid content was evaluated via flow cytometry using 4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene (BODIPY 493/503; Life Technologies) (Herber et al., 2010) . Briefly, 5x10 6 splenic or malignant peritoneal wash cells were stained for surface markers using antibodies that do not overlap with BODIPY 493/503, namely CD11c-APC, CD45-APC-Cy7, and CD11b-Pacific Blue, followed by staining with 500 ml of BODIPY 493/ 503 at 0.5 mg/ml in PBS for 15 min at room temperature in the dark. BODIPY 493/503 staining was detected in the PE channel. For intracellular cytokine staining, 5 3 10 6 cells from malignant peritoneal wash samples were stimulated for 6 hr in 10% FBS complete RPMI containing phorbol myristate acetate (PMA), Ionomycin (Calbiochem), and Brefeldin A (BioLegend). Cells were collected and stained for surface markers and intracellular cytokines (BioLegend) according to Foxp3/Transcription Factor Staining buffer set (eBioscience). Flow cytometry was performed on a LSRII instrument (BD Biosciences). Cell populations were sorted from peritoneal washes of OvCabearing mice or human ascites or tumor single-cell suspensions with a FACSAria sorter (BD Biosciences), and flow cytometry data were analyzed using FlowJo v.9 or v.10.
Statistical Analysis
Unless noted otherwise, all experiments were repeated at least two times and results were similar between repeats. Animal experiments used between three and six mice per group; p < 0.05 was considered to be statistically significant. All statistical analyses were done using Graph Pad Prism 5.0. Differences between the means of experimental groups were calculated using a two-tailed unpaired Student's t test. Error bars represent SEM from independent samples assayed within the represented experiments. Survival rates were compared using the log-rank test. All survival experiments used at least six mice per group. This number provides a 5% significance level and 95% power to detect differences in survival of 20% or greater.
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